Cargando…
A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue
Efforts to control SARS-CoV-2 have been challenged by the emergence of variant strains that have important implications for clinical and epidemiological decision making. Four variants of concern (VOCs) have been designated by the Centers for Disease Control and Prevention (CDC), namely, B.1.617.2 (d...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625484/ https://www.ncbi.nlm.nih.gov/pubmed/34829439 http://dx.doi.org/10.3390/diagnostics11112092 |
_version_ | 1784606432412303360 |
---|---|
author | Puligedda, Rama Devudu Al-Saleem, Fetweh H. Wirblich, Cristoph Kattala, Chandana Devi Jović, Marko Geiszler, Laura Devabhaktuni, Himani Feuerstein, Giora Z. Schnell, Matthias J. Sack, Markus Livornese, Lawrence L. Dessain, Scott K. |
author_facet | Puligedda, Rama Devudu Al-Saleem, Fetweh H. Wirblich, Cristoph Kattala, Chandana Devi Jović, Marko Geiszler, Laura Devabhaktuni, Himani Feuerstein, Giora Z. Schnell, Matthias J. Sack, Markus Livornese, Lawrence L. Dessain, Scott K. |
author_sort | Puligedda, Rama Devudu |
collection | PubMed |
description | Efforts to control SARS-CoV-2 have been challenged by the emergence of variant strains that have important implications for clinical and epidemiological decision making. Four variants of concern (VOCs) have been designated by the Centers for Disease Control and Prevention (CDC), namely, B.1.617.2 (delta), B.1.1.7 (alpha), B.1.351 (beta), and P.1 (gamma), although the last three have been downgraded to variants being monitored (VBMs). VOCs and VBMs have shown increased transmissibility and/or disease severity, resistance to convalescent SARS-CoV-2 immunity and antibody therapeutics, and the potential to evade diagnostic detection. Methods are needed for point-of-care (POC) testing to rapidly identify these variants, protect vulnerable populations, and improve surveillance. Antigen-detection rapid diagnostic tests (Ag-RDTs) are ideal for POC use, but Ag-RDTs that recognize specific variants have not yet been implemented. Here, we describe a mAb (2E8) that is specific for the SARS-CoV-2 spike protein N501 residue. The 2E8 mAb can distinguish the delta VOC from variants with the N501Y meta-signature, which is characterized by convergent mutations that contribute to increased virulence and evasion of host immunity. Among the N501Y-containing mutants formerly designated as VOCs (alpha, beta, and gamma), a previously described mAb, CB6, can distinguish beta from alpha and gamma. When used in a sandwich ELISA, these mAbs sort these important SARS-CoV-2 variants into three diagnostic categories, namely, (1) delta, (2) alpha or gamma, and (3) beta. As delta is currently the predominant variant globally, they will be useful for POC testing to identify N501Y meta-signature variants, protect individuals in high-risk settings, and help detect epidemiological shifts among SARS-CoV-2 variants. |
format | Online Article Text |
id | pubmed-8625484 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86254842021-11-27 A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue Puligedda, Rama Devudu Al-Saleem, Fetweh H. Wirblich, Cristoph Kattala, Chandana Devi Jović, Marko Geiszler, Laura Devabhaktuni, Himani Feuerstein, Giora Z. Schnell, Matthias J. Sack, Markus Livornese, Lawrence L. Dessain, Scott K. Diagnostics (Basel) Article Efforts to control SARS-CoV-2 have been challenged by the emergence of variant strains that have important implications for clinical and epidemiological decision making. Four variants of concern (VOCs) have been designated by the Centers for Disease Control and Prevention (CDC), namely, B.1.617.2 (delta), B.1.1.7 (alpha), B.1.351 (beta), and P.1 (gamma), although the last three have been downgraded to variants being monitored (VBMs). VOCs and VBMs have shown increased transmissibility and/or disease severity, resistance to convalescent SARS-CoV-2 immunity and antibody therapeutics, and the potential to evade diagnostic detection. Methods are needed for point-of-care (POC) testing to rapidly identify these variants, protect vulnerable populations, and improve surveillance. Antigen-detection rapid diagnostic tests (Ag-RDTs) are ideal for POC use, but Ag-RDTs that recognize specific variants have not yet been implemented. Here, we describe a mAb (2E8) that is specific for the SARS-CoV-2 spike protein N501 residue. The 2E8 mAb can distinguish the delta VOC from variants with the N501Y meta-signature, which is characterized by convergent mutations that contribute to increased virulence and evasion of host immunity. Among the N501Y-containing mutants formerly designated as VOCs (alpha, beta, and gamma), a previously described mAb, CB6, can distinguish beta from alpha and gamma. When used in a sandwich ELISA, these mAbs sort these important SARS-CoV-2 variants into three diagnostic categories, namely, (1) delta, (2) alpha or gamma, and (3) beta. As delta is currently the predominant variant globally, they will be useful for POC testing to identify N501Y meta-signature variants, protect individuals in high-risk settings, and help detect epidemiological shifts among SARS-CoV-2 variants. MDPI 2021-11-12 /pmc/articles/PMC8625484/ /pubmed/34829439 http://dx.doi.org/10.3390/diagnostics11112092 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Puligedda, Rama Devudu Al-Saleem, Fetweh H. Wirblich, Cristoph Kattala, Chandana Devi Jović, Marko Geiszler, Laura Devabhaktuni, Himani Feuerstein, Giora Z. Schnell, Matthias J. Sack, Markus Livornese, Lawrence L. Dessain, Scott K. A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue |
title | A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue |
title_full | A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue |
title_fullStr | A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue |
title_full_unstemmed | A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue |
title_short | A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue |
title_sort | strategy to detect emerging non-delta sars-cov-2 variants with a monoclonal antibody specific for the n501 spike residue |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625484/ https://www.ncbi.nlm.nih.gov/pubmed/34829439 http://dx.doi.org/10.3390/diagnostics11112092 |
work_keys_str_mv | AT puligeddaramadevudu astrategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT alsaleemfetwehh astrategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT wirblichcristoph astrategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT kattalachandanadevi astrategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT jovicmarko astrategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT geiszlerlaura astrategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT devabhaktunihimani astrategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT feuersteingioraz astrategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT schnellmatthiasj astrategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT sackmarkus astrategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT livorneselawrencel astrategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT dessainscottk astrategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT puligeddaramadevudu strategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT alsaleemfetwehh strategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT wirblichcristoph strategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT kattalachandanadevi strategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT jovicmarko strategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT geiszlerlaura strategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT devabhaktunihimani strategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT feuersteingioraz strategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT schnellmatthiasj strategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT sackmarkus strategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT livorneselawrencel strategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue AT dessainscottk strategytodetectemergingnondeltasarscov2variantswithamonoclonalantibodyspecificforthen501spikeresidue |